Despite intense investigation, mechanisms that facilitate the emergence of the
pre-eclampsia phenotype in women are still unknown. Placental
hypoxia,
hypertension,
proteinuria and oedema are the principal clinical features of this disease. It is speculated that
hypoxia-driven disruption of the angiogenic balance involving
vascular endothelial growth factor (
VEGF)/placenta-derived
growth factor (PLGF) and soluble Fms-like
tyrosine kinase-1 (sFLT-1, the soluble form of
VEGF receptor 1) might contribute to some of the maternal symptoms of
pre-eclampsia. However,
pre-eclampsia does not develop in all women with high sFLT-1 or low PLGF levels, and it also occurs in some women with low sFLT-1 and high PLGF levels. Moreover, recent experiments strongly suggest that several soluble factors affecting the vasculature are probably elevated because of placental
hypoxia in the pre-eclamptic women, indicating that upstream molecular defect(s) may contribute to
pre-eclampsia. Here we show that pregnant mice deficient in
catechol-O-methyltransferase (COMT) show a
pre-eclampsia-like phenotype resulting from an absence of
2-methoxyoestradiol (2-ME), a natural metabolite of
oestradiol that is elevated during the third trimester of normal human pregnancy.
2-ME ameliorates all
pre-eclampsia-like features without toxicity in the Comt(-/-) pregnant mice and suppresses placental
hypoxia,
hypoxia-inducible factor-1alpha expression and sFLT-1 elevation. The levels of COMT and
2-ME are significantly lower in women with severe
pre-eclampsia. Our studies identify a genetic mouse model for
pre-eclampsia and suggest that
2-ME may have utility as a plasma and urine diagnostic marker for this disease, and may also serve as a therapeutic supplement to prevent or treat this disorder.